Surgery Partners (SGRY) Competitors

$14.48 +0.17 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$14.48 -0.01 (-0.03%)

As of 06:39 PM Eastern

SGRY vs. THC, HIMS, CELC, CAI, and PACS

Should you buy Surgery Partners stock or one of its competitors? MarketBeat compares Surgery Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Surgery Partners include Tenet Healthcare (THC), Hims & Hers Health (HIMS), Celcuity (CELC), Caris Life Sciences (CAI), and PACS Group (PACS).

How does Surgery Partners compare to Tenet Healthcare?

Surgery Partners (NASDAQ:SGRY) and Tenet Healthcare (NYSE:THC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Tenet Healthcare has a net margin of 7.94% compared to Surgery Partners' net margin of -2.28%. Tenet Healthcare's return on equity of 25.55% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Tenet Healthcare	7.94%	25.55%	5.15%

In the previous week, Tenet Healthcare had 1 more articles in the media than Surgery Partners. MarketBeat recorded 7 mentions for Tenet Healthcare and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat Tenet Healthcare's score of 0.63 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenet Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Surgery Partners has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market. Comparatively, Tenet Healthcare has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

95.4% of Tenet Healthcare shares are owned by institutional investors. 2.7% of Surgery Partners shares are owned by company insiders. Comparatively, 0.8% of Tenet Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tenet Healthcare has higher revenue and earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Tenet Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A
Tenet Healthcare	$21.31B	0.80	$1.41B	$19.23	10.35

Surgery Partners presently has a consensus target price of $22.18, suggesting a potential upside of 53.19%. Tenet Healthcare has a consensus target price of $244.16, suggesting a potential upside of 22.73%. Given Surgery Partners' higher probable upside, equities analysts plainly believe Surgery Partners is more favorable than Tenet Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Tenet Healthcare	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Tenet Healthcare beats Surgery Partners on 12 of the 16 factors compared between the two stocks.

How does Surgery Partners compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Surgery Partners (NASDAQ:SGRY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Hims & Hers Health currently has a consensus target price of $29.50, suggesting a potential upside of 21.73%. Surgery Partners has a consensus target price of $22.18, suggesting a potential upside of 53.19%. Given Surgery Partners' stronger consensus rating and higher probable upside, analysts plainly believe Surgery Partners is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Hims & Hers Health has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

In the previous week, Hims & Hers Health had 69 more articles in the media than Surgery Partners. MarketBeat recorded 75 mentions for Hims & Hers Health and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat Hims & Hers Health's score of 0.02 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	17 Very Positive mention(s)	11 Positive mention(s)	10 Neutral mention(s)	23 Negative mention(s)	6 Very Negative mention(s)	Neutral
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a net margin of -0.56% compared to Surgery Partners' net margin of -2.28%. Hims & Hers Health's return on equity of 6.10% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Surgery Partners	-2.28%	1.04%	0.41%

Hims & Hers Health has higher earnings, but lower revenue than Surgery Partners. Hims & Hers Health is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.37B	2.33	$128.37M	-$0.09	N/A
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 2.7% of Surgery Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Hims & Hers Health beats Surgery Partners on 10 of the 16 factors compared between the two stocks.

How does Surgery Partners compare to Celcuity?

Celcuity (NASDAQ:CELC) and Surgery Partners (NASDAQ:SGRY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Celcuity currently has a consensus target price of $134.50, suggesting a potential downside of 0.16%. Surgery Partners has a consensus target price of $22.18, suggesting a potential upside of 53.19%. Given Surgery Partners' higher probable upside, analysts plainly believe Surgery Partners is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Celcuity has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market.

In the previous week, Celcuity had 5 more articles in the media than Surgery Partners. MarketBeat recorded 11 mentions for Celcuity and 6 mentions for Surgery Partners. Celcuity's average media sentiment score of 1.28 beat Surgery Partners' score of 1.13 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity has a net margin of 0.00% compared to Surgery Partners' net margin of -2.28%. Surgery Partners' return on equity of 1.04% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-203.17%	-52.68%
Surgery Partners	-2.28%	1.04%	0.41%

Surgery Partners has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 2.7% of Surgery Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Surgery Partners beats Celcuity on 8 of the 15 factors compared between the two stocks.

How does Surgery Partners compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Surgery Partners (NASDAQ:SGRY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Caris Life Sciences has higher earnings, but lower revenue than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.31	-$68.09M	-$7.61	N/A
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A

Caris Life Sciences currently has a consensus target price of $27.56, suggesting a potential upside of 80.69%. Surgery Partners has a consensus target price of $22.18, suggesting a potential upside of 53.19%. Given Caris Life Sciences' higher possible upside, equities analysts plainly believe Caris Life Sciences is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Caris Life Sciences had 16 more articles in the media than Surgery Partners. MarketBeat recorded 22 mentions for Caris Life Sciences and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat Caris Life Sciences' score of 0.16 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a net margin of 3.75% compared to Surgery Partners' net margin of -2.28%. Caris Life Sciences' return on equity of 98.28% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Surgery Partners	-2.28%	1.04%	0.41%

Summary

Caris Life Sciences beats Surgery Partners on 8 of the 13 factors compared between the two stocks.

How does Surgery Partners compare to PACS Group?

PACS Group (NYSE:PACS) and Surgery Partners (NASDAQ:SGRY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

PACS Group currently has a consensus target price of $45.60, suggesting a potential upside of 14.80%. Surgery Partners has a consensus target price of $22.18, suggesting a potential upside of 53.19%. Given Surgery Partners' higher possible upside, analysts plainly believe Surgery Partners is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, PACS Group had 7 more articles in the media than Surgery Partners. MarketBeat recorded 13 mentions for PACS Group and 6 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 1.13 beat PACS Group's score of 1.06 indicating that Surgery Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PACS Group has higher revenue and earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.19	$191.54M	$1.56	25.46
Surgery Partners	$3.31B	0.57	-$77.90M	-$0.60	N/A

PACS Group has a net margin of 4.49% compared to Surgery Partners' net margin of -2.28%. PACS Group's return on equity of 26.47% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Surgery Partners	-2.28%	1.04%	0.41%

PACS Group has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Surgery Partners has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Summary

PACS Group beats Surgery Partners on 11 of the 15 factors compared between the two stocks.

Get Surgery Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGRY vs. The Competition

Export

Metric	Surgery Partners	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.87B	$8.35B	$6.34B	$12.38B
Dividend Yield	N/A	3.03%	2.80%	5.35%
P/E Ratio	-24.13	21.76	20.90	25.61
Price / Sales	0.57	16.95	549.47	78.77
Price / Cash	8.38	81.29	43.26	56.33
Price / Book	0.61	5.65	9.93	6.96
Net Income	-$77.90M	$183.43M	$3.55B	$333.52M
7 Day Performance	1.19%	0.14%	-0.33%	0.45%
1 Month Performance	10.53%	5.21%	1.34%	4.06%
1 Year Performance	-36.41%	4.75%	41.10%	36.24%

Surgery Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGRY Surgery Partners	4.0742 of 5 stars	$14.48 +1.2%	$22.18 +53.2%	-37.6%	$1.87B	$3.31B	N/A	16,000	Positive News High Trading Volume
THC Tenet Healthcare	4.6184 of 5 stars	$185.24 +1.1%	$242.89 +31.1%	+24.0%	$16.06B	$21.31B	9.63	99,000	Analyst Downgrade
HIMS Hims & Hers Health	4.2252 of 5 stars	$27.25 -0.6%	$32.53 +19.4%	-62.3%	$6.25B	$2.35B	53.43	2,442	Trending News Earnings Report Analyst Forecast Options Volume
CELC Celcuity	1.7657 of 5 stars	$144.98 +15.4%	$134.50 -7.2%	+1,050.4%	$6.07B	N/A	N/A	40	News Coverage Positive News High Trading Volume
CAI Caris Life Sciences	4.3482 of 5 stars	$18.69 +1.2%	$28.86 +54.4%	N/A	$5.22B	$812.03M	N/A	1,846	Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGRY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Surgery Partners (SGRY) Competitors

SGRY vs. THC, HIMS, CELC, CAI, and PACS

How does Surgery Partners compare to Tenet Healthcare?

Summary

How does Surgery Partners compare to Hims & Hers Health?

Summary

How does Surgery Partners compare to Celcuity?

Summary

How does Surgery Partners compare to Caris Life Sciences?

Summary

How does Surgery Partners compare to PACS Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGRY vs. The Competition

Surgery Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Surgery Partners (SGRY) Competitors

SGRY vs. THC, HIMS, CELC, CAI, and PACS

How does Surgery Partners compare to Tenet Healthcare?

Is SGRY or THC more profitable?

Does the media favor SGRY or THC?

Which has more risk and volatility, SGRY or THC?

Do institutionals & insiders hold more shares of SGRY or THC?

Which has preferable earnings & valuation, SGRY or THC?

Do analysts recommend SGRY or THC?

Summary

How does Surgery Partners compare to Hims & Hers Health?

Do analysts recommend HIMS or SGRY?

Which has more volatility & risk, HIMS or SGRY?

Does the media favor HIMS or SGRY?

Is HIMS or SGRY more profitable?

Which has better valuation and earnings, HIMS or SGRY?

Do insiders and institutionals hold more shares of HIMS or SGRY?

Summary

How does Surgery Partners compare to Celcuity?

Do analysts recommend CELC or SGRY?

Which has more volatility & risk, CELC or SGRY?

Does the media favor CELC or SGRY?

Is CELC or SGRY more profitable?

Which has better valuation and earnings, CELC or SGRY?

Do insiders and institutionals hold more shares of CELC or SGRY?

Summary

How does Surgery Partners compare to Caris Life Sciences?

Which has preferable valuation & earnings, CAI or SGRY?

Do analysts prefer CAI or SGRY?

Does the media refer more to CAI or SGRY?

Is CAI or SGRY more profitable?

Summary

How does Surgery Partners compare to PACS Group?

Do analysts prefer PACS or SGRY?

Does the media favor PACS or SGRY?

Which has preferable valuation & earnings, PACS or SGRY?

Is PACS or SGRY more profitable?

Which has more volatility and risk, PACS or SGRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGRY vs. The Competition

Surgery Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools